Lee, S.J., Lee, J., Lee, J., Park, S.H., Park, J.O., Park, Y.S., Lim, H.Y., Kim, K.M., Do, I.G., Jung, S.H., Yim, D.S. and Kang, W.K. (2013) Phase II Trial of Capecitabine and Everolimus (RAD001) Combination in Refractory Gastric Cancer Patients. Investigational New Drugs, 31, 1580-1586.
https://doi.org/10.1007/s10637-013-0022-0

has been cited by the following article:

• TITLE: Advancement on Clinical Application of mTOR Inhibitors in Gastrointestinal Cancers

  AUTHORS: Yingqi Feng, Yongshou Chen, Yixin Ren, Shuang Cao, Heng Zhang

  KEYWORDS: mTOR, Gastrointestinal Cancers, Targeted Drug, Sensitization

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.8 No.4, April 10, 2020

  ABSTRACT: Gastrointestinal cancers, including esophageal cancer, gastric cancer, liver cancer, pancreatic cancer, colorectal cancer, are serious threats to people's health, and traditional therapeutic drugs have limited effect on them. Signaling pathway related to mammalian target of rapamycin (mTOR) plays a very important role either in the germination or development of multiple gastrointestinal cancers. Inhibiting mTOR can effectively impede the development of tumor and improve the sensitivity of tumor to radiotherapy or chemotherapy. The research on the application of mTOR inhibitors in gastrointestinal cancers increases with years. A lot of operational schemes independent or combined with others are being explored, some of which are worthy of attention. This paper summarizes the data of all published clinical trials and reviews the clinical application of mTOR inhibitors in the treatment of gastrointestinal cancers in recent years.